BE XR OD vs IR BID - which Cmax for IR? [Regulatives / Guidelines]

posted by jag009  – NJ, 2020-05-11 08:29 (1418 d 00:20 ago) – Posting: # 21417
Views: 3,389

❝ I would like to have the help of the forum participants on a tricky question, ie which IR Cmax should be considered to assess the potential bioequivalence between an IR formulation administered BID and an XR formulation administered OD on day 1 and at steady-state. This is for a submission to FDA.


Not sure if the following will answer your Q exactly and whether it still exists on FDA website (or they blacked out the results):
Look for Ultram ER at Drugs@FDA.
Similar approach (Don't ask how I know :))

J

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
97 visitors (0 registered, 97 guests [including 6 identified bots]).
Forum time: 07:50 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5